Plus   Neg

Amgen Inc. (AMGN) Has Risen To A New High For The Year

Amgen Inc. (AMGN) announced after the bell Tuesday that its Phase 3 trial of talimogene laherparepvec for the treatment of melanoma met its primary endpoint.

Amgen has been climbing for the majority of early trade Wednesday and is now up 2.32 at $94.72. The stock has risen above a 3-week range and has set a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT